Govt advisory panel to review trial data on Serum Institute qHPV vaccine against cervical cancer

Published On 2022-06-27 05:59 GMT | Update On 2022-06-27 05:59 GMT

New Delhi: The government advisory panel NTAGI is likely to review on June 28 trial data on India's first quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, developed by the Serum Institute, official sources said on Sunday.

A separate HPV working group of the National Technical Advisory Group on Immunisation (NTAGI) had examined on June 8 the clinical trial data and usefulness of the vaccine for inclusion in the national immunisation programme, they said.

In the meantime, Serum Institute of India (SII) Director for Government and Regulatory Affairs Prakash Kumar Singh applied to the Drugs Controller General of India (DCGI) seeking market authorisation for the vaccine after the phase 2/3 clinical trial was completed with the support of the Department of Biotechnology to ensure its early availability in the country.

According to official sources, based on this application, the subject expert committee of the Central Drugs Standard Control Organisation (CDSCO) had recommended on June 15 granting market authorisation to the jab. The approval of the DCGI is still awaited.

Read also: CDSCO panel recommends market nod for Serum Institute qHPV vaccine against cervical cancer

According to the application submitted by Singh, the vaccine, CERVAVAC, has demonstrated robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all doses and age groups.

The application mentioned that lakhs of women are diagnosed every year with cervical and a few other types of cancer and the death ratio is very high.

Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.

"Also, it is noteworthy that presently our country is fully dependent on foreign manufacturers for the HPV vaccine. In line with the philosophy of our group and under leadership of our CEO, Dr Adar C Poonawalla, it has always been our endeavour to make available high quality 'Made in India' vaccines at affordable price for people of our country and world at large," Singh had said in the application.

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Govt advisory panel to review trial data on Serum Institute qHPV vaccine against cervical cancer

Similar News

Lupin bags USFDA approval for Multiple myeloma treatment

Biocon Biologics wins USFDA nod for Bosaya and Aukelso, Denosumab Biosimilars

Cocrystals of Approved APIs to Be Treated as New Drugs, Clarifies CDSCO

India ranks among top global contributors in adverse event reporting: DCGI

Marketers Linked to Defaulting Pharma Units Under DCGI Lens

Intas Pharma Secures CDSCO Panel Approval for Post-Marketing Study of Tacrolimus Enema

Health Authorities Crack Down on OTC Sale of Antibiotics, NRx Drugs in Visakhapatnam

Merck gets USFDA Breakthrough Therapy Designation for Raludotatug deruxtecan for Platinum-Resistant Ovarian Cancer